<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02888236</url>
  </required_header>
  <id_info>
    <org_study_id>LP0058-1072</org_study_id>
    <nct_id>NCT02888236</nct_id>
  </id_info>
  <brief_title>LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris</brief_title>
  <official_title>LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of LEO 32731 in the treatment of psoriasis vulgaris
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigation of the efficacy of LEO 32731 30 mg as compared to placebo after 16
      weeks of oral treatment of psoriasis vulgaris
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">July 6, 2017</completion_date>
  <primary_completion_date type="Actual">June 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI) at week 16</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Physician's Global Assessment of Disease Severity (PGA) treatment success, defined as clear or almost clear at week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch evaluated by itch Numerical Rating Scale (NRS) at week 16</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 32731 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 32731 30 mg two times daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 32731 Placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LEO 32731 placebo two times daily for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 32731</intervention_name>
    <arm_group_label>LEO 32731 tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 32731 Placebo</intervention_name>
    <arm_group_label>LEO 32731 Placebo tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Aged between 18 years and 65.

          -  Males or females of non-childbearing potential.

          -  Clinical diagnosis of psoriasis vulgaris with or without psoriatic arthritis

          -  Have moderate to severe psoriasis vulgaris

          -  Candidates of systemic anti-psoriatic treatment and/or phototherapy

        Exclusion Criteria:

          -  Subjects with therapy resistant psoriasis

          -  Previously exposed to apremilast

          -  Systemic treatment with biological therapies, whether marketed or not, with a possible
             effect on psoriasis vulgaris

          -  Systemic treatment with all other therapies (other than biologics) with a possible
             effect on psoriasis vulgaris
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Philipp, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Dept. of Dermatology</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2016</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

